Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq debut

Barinthus Biotherapeutics

30/04/2021 17:06

April 30 (Reuters) - American depositary shares of
Vaccitech, which co-invented the COVID-19 vaccine developed by
AstraZeneca Plc  AZN.L  and Oxford University, fell nearly 20%
in their market debut on Friday, giving the biotech firm a
market value of about $464 million.
    The company's shares opened at $13.62, below the initial
public offering price of $17. 

 (Reporting by Vishwadha Chander in Bengaluru; Editing by Aditya
Soni)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))